Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-01, Vol.388 (1), p.44-54
Hauptverfasser:	Yaeger, Rona, Weiss, Jared, Pelster, Meredith S., Spira, Alexander I., Barve, Minal, Ou, Sai-Hong I., Leal, Ticiana A., Bekaii-Saab, Tanios S., Paweletz, Cloud P., Heavey, Grace A., Christensen, James G., Velastegui, Karen, Kheoh, Thian, Der-Torossian, Hirak, Klempner, Samuel J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Cancer Cancer therapies Cetuximab - administration & dosage Cetuximab - adverse effects Cetuximab - therapeutic use Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - secondary Drug therapy Epidermal growth factor Gastroenterology Gastrointestinal Tract Cancer Genetics Growth factors Hematology Humans Intravenous administration K-Ras protein Metastases Metastasis Monoclonal antibodies Mutants Mutation Oncology Patients Piperazines - therapeutic use Proteins Proto-Oncogene Proteins p21(ras) - genetics Response rates Review boards Survival Targeted cancer therapy Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2212419